全程监测加联合用药对乙型肝炎疗效分析

Analysis on Directly Observed Treatment Adding Combined Therapy for Chronic Hepatitis B to Fibrosis by Sera Test

目的探索合理而有效的慢性乙型肝炎长期治疗方案,分析全程督导加联合用药对慢性乙型肝炎治疗效果。方法对在1996年～2002年间二次治疗的678例慢性乙型肝炎患者,进行抗病毒或不进行抗病毒治疗,两次检测患者血清Ⅳ-C和PCⅢ,多因素回归统计学分析。结果678例患者进行多因素回归分析表明,抗病毒治疗时间在所有因素中影响最大;其次为监督治疗时间,紧接着是抗纤维化治疗时间,最后分别是非特异性免疫治疗时间和其它治疗方案时间。人为分组后,全程督导治疗加联合治疗的治疗组治疗效果较好,血清学检测指标与其它组相比,有统计学差异。结论在全程监督治疗的情况下,联合抗病毒治疗(干扰素),免疫调节(胸腺肽)和抗纤维化的联合治疗为最佳治疗方案,适宜于慢性乙型肝炎长期抗纤维化治疗。

Objective To look for a reasonable and effective therapy scheme to chronic active hepatitis B.Methods 678 patients of chronic active hepatitis B were studied that had received twice of treatments include anti-virus therapy or not from 1996 to 2002.After twice of sera test type Ⅳ collagen(Ⅳ-C),procollagen type Ⅲ(PCⅢ),the data were analyzed by statistics.Results Regression analysis of statistics to Ⅳ-C,PCⅢ from the most effective patients after therapy showed the factor of anti-virus therapy had the greatest influence;the followings are the directly observed treatment methods on all patients and analysis by t-test,the data showed the directly observed treatment adding combined therapy,that is anti-virus therapy,anti-fibrosis therapy and modulated immune therapy was most suitable therapy scheme for patients.Conclusion Under the directly observed treatment,combining anti-virus therapy(interfron) ,anti-fibrosis therapy and modulated immune therapy(thymosin) was a suitable long term fibrosis therapy for chronic active hepatitis B.